Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
Condition: Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Noncontiguous Stage II Mantle Cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; T-cell Large Granular Lymphocyte Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
MeSH terms: Burkitt Lymphoma; Mycoses; Lymphoma; Leukemia; Leukemia, Myeloid; Multiple Myeloma; Neoplasms, Plasma Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell; Hodgkin Disease; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Plasmablastic Lymphoma; Mycosis Fungoides; Leukemia, Myelomonocytic, Acute; Leukemia, Myelomonocytic, Chronic; Lymphoma, B-Cell; Sezary Syndrome; Lymphoma, T-Cell, Cutaneous; Leukemia, Myelomonocytic, Juvenile; Polycythemia Vera; Lymphoma, Large-Cell, Anaplastic; Leukemia, Hairy Cell; Leukemia, Myeloid, Chronic-Phase; Blast Crisis; Lymphomatoid Granulomatosis; Leukemia, Myeloid, Accelerated Phase; Lymphoma, Extranodal NK-T-Cell; Leukemia, Prolymphocytic; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Plasmacytoma; Intraocular Lymphoma; Leukemia, Large Granular Lymphocytic; Immunoglobulin Light-chain Amyloidosis; Leukemia, Mast-Cell; Myelodysplastic Syndromes; Primary Myelofibrosis; Polycythemia; Thrombocytosis; Thrombocythemia, Essential; Lymphoproliferative Disorders; Immunoblastic Lymphadenopathy; Hypereosinophilic Syndrome; Leukemia, Neutrophilic, Chronic; Amyloidosis; Syndrome; Recurrence
Study type: Interventional

Summary: 
      This clinical trial studies massage therapy given by caregiver in treating quality of life of
      young patients undergoing treatment for cancer. Massage therapy given by a caregiver may
      improve the quality of life of young patients undergoing treatment for cancer
    

Detailed description: 
      PRIMARY OBJECTIVES:

      I. To determine the feasibility and acceptability of conducting a massage intervention with
      childhood cancer patients and their primary caregivers.

      II. To investigate feasibility of implementing a brief targeted massage training protocol
      with caregivers.

      III. To identify barriers to recruitment, intervention adherence, and full study completion
      by consented families.

      IV. To assess preliminary effectiveness of the massage intervention in reducing caregiver and
      child psychological distress (anxiety, depression, parenting stress) and promoting child
      health-related quality of life.

      V. To compare outcome data between two intervention arms (TOUCH: child massage only; TOUCH+:
      Caregiver massage plus child massage) and between each arm and a wait list control condition.

      VI. To utilize the pilot data in a development of contextually specific and targeted grant
      application for a fully powered randomized controlled trial of the efficacy of caregiver
      massage of children undergoing treatment for cancer.

      SECONDARY OBJECTIVES:

      I. To investigate reciprocal change in self-reported psychosocial functioning within the
      caregiver-child dyad from baseline to post-intervention.

      II. To assess impact of massage intervention upon levels of a stress biomarker (cortisol) in
      caregivers and children and to assess associations of cortisol levels with self-reported
      psychosocial functioning.

      OUTLINE: Patients and their caregivers are randomized to 1 of 3 treatment arms.

      ARM I (WAITLIST CONTROL GROUP): Patients and caregivers receive standard of care and are
      offered the massage intervention after 8 weeks.

      ARM II (TOUCH): Caregivers undergo a 60-minute training session on simple massage techniques,
      including the "Massage Toolkit," comprising Swedish Massage and Trigger Point Therapy
      Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed
      massage therapist. Caregivers are instructed to massage their children for at least 3
      20-minute sessions per week for 8 weeks.

      ARM III (TOUCH+): Caregivers undergo a 60-minute training session on simple massage
      techniques, including the "Massage Toolkit," comprising Swedish Massage and Trigger Point
      Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a
      licensed massage therapist. Caregivers are instructed to massage their children for at least
      3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the
      massage therapist.

      Patients complete questionnaires at weeks 0, 8, and 16.

      After completion of study treatment, patients and caregivers are followed for 8 weeks.
    

Intervention name(s): massage therapy; questionnaire administration; quality-of-life assessment; intervention by caregiver; standard follow-up care
Intervention type(s): Procedure; Other; Procedure; Other; Procedure
Intervention description(s): Undergo massage therapy; Ancillary studies; Ancillary studies; Undergo massage by caregiver; Undergo standard follow-up care
Other intervention name(s): massage; therapeutic massage; quality of life assessment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Supportive Care